| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 15, 2023Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study
Durham, NC June 15, 2023 – Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101...
-
May 18, 2023January 2024 PDUFA date expected
South San Francisco, CA, May 18, 2023 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA)...
-
Apr 21, 2023
South San Francisco, CA, April 21, 2023 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...
-
Apr 16, 2023Transaction delivers immediate value and liquidity to Satsuma stockholders
South San Francisco, CA, April 16, 2023 – Satsuma Pharmaceuticals, Inc. (“Satsuma”) (Nasdaq: STSA) today announced that it has entered into a definitive agreement to be acquired by Shin...
-
Mar 28, 2023
- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted...
-
Feb 2, 2023
South San Francisco, CA, February 2, 2023 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a...